Royal Hound Unveils Phase II Clinical Trial Results for Supplement Ingredients – Nearing Entry into the Chinese Market

Pet pharmaceutical company Royal Hound has disclosed the results of Phase II clinical trials on the ingredients of its supplement products as it prepares to enter the Chinese market. From September 22 to 25, Royal Hound presented these research findings in a poster presentation at the IUNS conference in Beijing, China, demonstrating the effectiveness and competitive edge of its products.

In this clinical trial, Royal Hound’s research team focused on verifying the effects of key ingredients aimed at enhancing immunity and boosting antioxidant function. According to the study, these ingredients activate T-cells, which play a critical role in the immune system of pets, promoting the production of essential cytokines that strengthen immune responses, thus contributing significantly to the maintenance of pet health. Additionally, the research team observed a meaningful increase in specific antioxidant proteins within the test subjects, confirming that these ingredients can help restore antioxidant capacity diminished by aging, which has a positive effect on overall energy and vitality in pets.

The head of Royal Hound’s research department emphasized that this presentation reflects the company’s research capabilities and the efficacy of its products on a global stage. He stated, “The Phase II clinical trial results validate our product as an effective solution for long-term pet health management. Given the rapid growth of the pet market in China, we anticipate that Royal Hound’s products will set a new standard in this sector.” China represents a critical market with increasing demand for premium pet supplements due to a rising pet population, and this presentation is expected to positively impact Royal Hound’s future success in the Chinese market.

Royal Hound also expressed confidence that its solutions will earn the trust of Chinese consumers. A company representative remarked, “There is already a rising demand for premium pet supplements in the Chinese market, and we plan to strengthen our product positioning with a locally tailored strategy.”

These research results mark an important step in Royal Hound’s journey to establishing a leading position in the global pet healthcare market. The company intends to continue verifying the efficacy of its products through further research and trials, while also strengthening its marketing and R&D capabilities in other key markets, including the United States and Europe.